Question:
You are tasked with answering the user's question using the provided context, which includes financial statements (Income Statements, Balance Sheets, and Cash Flow Statements) and financial news articles in multiple languages (English, Chinese, Japanese, Spanish, and Greek). Please provide a detailed and well-supported answer based on the information available. Limit your response to 100 words or fewer. If you cannot answer the question or if no relevant evidence is found, write “None”.

Answer Format:
Answer: {Answer using the financial statement.}
News Evidence: {Verify your answer using quote(s) from the financial news. Write “None” if no news evidence is available.}
Context:
Financial Statements:
| Column 1                                                                                | Column 2   | Column 3           | Column 4   | Column 5          | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:---------------------------------------------------------------------------------------------------|:-----------|:-------------------|:-----------|:------------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | September 29, 2024 |            | December 31, 2023 |            |            |            |            |             |             |             |             |             |             |
| Assets                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current assets:                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Cash and cash equivalents (Note 4)                                                                 |            | $19,980            |            | 21,859            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Marketable securities                                                                              |            | 317                |            | 1,068             |            |            |            |            |             |             |             |             |             |             |
| Accounts receivable, trade, less allowances $153(2023, $166)                                       |            | 16,174             |            | 14,873            |            |            |            |            |             |             |             |             |             |             |
| Inventories (Note 2)                                                                               |            | 12,603             |            | 11,181            |            |            |            |            |             |             |             |             |             |             |
| Prepaid expenses and other                                                                         |            | 4,175              |            | 4,514             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current assets                                                                               |            | 53,249             |            | 53,495            |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment at cost                                                              |            | 49,274             |            | 47,776            |            |            |            |            |             |             |             |             |             |             |
| Less: accumulated depreciation                                                                     |            | (28,795)           |            | (27,878)          |            |            |            |            |             |             |             |             |             |             |
| Property, plant and equipment, net                                                                 |            | 20,479             |            | 19,898            |            |            |            |            |             |             |             |             |             |             |
| Intangible assets, net (Note 3)                                                                    |            | 39,490             |            | 34,175            |            |            |            |            |             |             |             |             |             |             |
| Goodwill (Note 3)                                                                                |            | 44,799             |            | 36,558            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 9,349              |            | 9,279             |            |            |            |            |             |             |             |             |             |             |
| Other assets                                                                                |            | 10,921             |            | 14,153            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total assets                                                                                |            | $178,287           |            | 167,558           |            |            |            |            |             |             |             |             |             |             |
| Liabilities and shareholders’ equity                                                               |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Current liabilities:                                                                               |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Loans and notes payable                                                                            |            | $4,462             |            | 3,451             |            |            |            |            |             |             |             |             |             |             |
| Accounts payable                                                                                |            | 8,954              |            | 9,632             |            |            |            |            |             |             |             |             |             |             |
| Accrued liabilities                                                                                |            | 11,450             |            | 10,212            |            |            |            |            |             |             |             |             |             |             |
| Accrued rebates, returns and promotions                                                            |            | 18,439             |            | 16,001            |            |            |            |            |             |             |             |             |             |             |
| Accrued compensation and employee related obligations                                              |            | 3,620              |            | 3,993             |            |            |            |            |             |             |             |             |             |             |
| Accrued taxes on income (Note 5)                                                                   |            | 4,834              |            | 2,993             |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total current liabilities                                                                          |            | 51,759             |            | 46,282            |            |            |            |            |             |             |             |             |             |             |
| Long-term debt (Note 4)                                                                            |            | 31,289             |            | 25,881            |            |            |            |            |             |             |             |             |             |             |
| Deferred taxes on income (Note 5)                                                                  |            | 2,952              |            | 3,193             |            |            |            |            |             |             |             |             |             |             |
| Employee related obligations (Note 6)                                                              |            | 6,852              |            | 7,149             |            |            |            |            |             |             |             |             |             |             |
| Long-term taxes payable (Note 5)                                                                   |            | 354                |            | 2,881             |            |            |            |            |             |             |             |             |             |             |
| Other liabilities                                                                                |            | 14,923             |            | 13,398            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Total liabilities                                                                                |            | $108,129           |            | 98,784            |            |            |            |            |             |             |             |             |             |             |
| Commitments and Contingencies (Note 11)                                                            |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Shareholders’ equity:                                                                              |            |                    |            |                   |            |            |            |            |             |             |             |             |             |             |
| Common stock — par value $1.00per share (authorized4,320,000,000shares; issued3,119,843,000shares) |            | $3,120             |            | 3,120             |            |            |            |            |             |             |             |             |             |             |
| Accumulated other comprehensive income (loss) (Note 7)                                             |            | (12,522)           |            | (12,527)          |            |            |            |            |             |             |             |             |             |             |
| Retained earnings and Additional paid-in capital                                                   |            | 155,179            |            | 153,843           |            |            |            |            |             |             |             |             |             |             |
| Less: common stock held in treasury, at cost (712,545,000and712,765,000shares)                     |            | 75,619             |            | 75,662            |            |            |            |            |             |             |             |             |             |             |
| Total shareholders’ equity                                                                         |            | $70,158            |            | 68,774            |            |            |            |            |             |             |             |             |             |             |
| Total liabilities and shareholders’ equity                                                         |            | $178,287           |            | 167,558           |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                                                                | Column 2   | Column 3                 | Column 4   | Column 5       | Column 6   | Column 7   | Column 8   | Column 9   | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   |
|:-------------------------------------------------------------------------------------------------------------------------|:-----------|:-------------------------|:-----------|:---------------|:-----------|:-----------|:-----------|:-----------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | Fiscal Nine Months Ended |            |                |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            | September 29,2024        |            | October 1,2023 |            |            |            |            |             |             |             |             |             |             |
| Cash flows from operating activities                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Net earnings                                                                                |            | $10,635                  |            | 31,104         |            |            |            |            |             |             |             |             |             |             |
| Adjustments to reconcile net earnings to cash flows from operating activities:                                           |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Depreciation and amortization of property and intangibles                                                                |            | 5,443                    |            | 5,643          |            |            |            |            |             |             |             |             |             |             |
| Stock based compensation                                                                                |            | 938                      |            | 984            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Asset write-downs                                                                                |            | 379                      |            | 820            |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Charge for purchase of in-process research and development assets                                                        |            | 1,252                    |            | —              |            |            |            |            |             |             |             |             |             |             |
| Gain on Kenvue separation                                                                                |            | —                        |            | (20,984)       |            |            |            |            |             |             |             |             |             |             |
| Net gain on sale of assets/businesses                                                                                |            | (225)                    |            | (117)          |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Deferred tax provision                                                                                |            | (2,167)                  |            | (1,782)        |            |            |            |            |             |             |             |             |             |             |
| Credit losses and accounts receivable allowances                                                                         |            | (11)                     |            | —              |            |            |            |            |             |             |             |             |             |             |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures:                                    |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts receivable                                                                                |            | (1,259)                  |            | (851)          |            |            |            |            |             |             |             |             |             |             |
| Increase in inventories                                                                                |            | (1,038)                  |            | (1,447)        |            |            |            |            |             |             |             |             |             |             |
| Increase in accounts payable and accrued liabilities                                                                     |            | 2,713                    |            | 664            |            |            |            |            |             |             |             |             |             |             |
| Decrease/(Increase) in other current and non-current assets                                                              |            | 949                      |            | (1,366)        |            |            |            |            |             |             |             |             |             |             |
| (Decrease)/Increase in other current and non-current liabilities                                                         |            | (326)                    |            | 2,260          |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Net cash flows from operating activities                                                                                |            | 17,283                   |            | 14,928         |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Cash flows from investing activities                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Additions to property, plant and equipment                                                                               |            | (2,812)                  |            | (2,954)        |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the disposal of assets/businesses, net (Note 10)                                                           |            | 623                      |            | 237            |            |            |            |            |             |             |             |             |             |             |
| Acquisitions, net of cash acquired (Note 10)                                                                             |            | (15,145)                 |            | —              |            |            |            |            |             |             |             |             |             |             |
| Purchases of in-process research and development assets (Note 10)                                                        |            | (1,250)                  |            | —              |            |            |            |            |             |             |             |             |             |             |
| Purchases of investments                                                                                |            | (1,464)                  |            | (9,981)        |            |            |            |            |             |             |             |             |             |             |
| Sales of investments                                                                                |            | 2,172                    |            | 15,787         |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                                                |            | 699                      |            | (917)          |            |            |            |            |             |             |             |             |             |             |
| Other (including capitalized licenses and milestones)                                                                    |            | (102)                    |            | (92)           |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Net cash (used by) / from  investing activities                                                                          |            | (17,279)                 |            | 2,080          |            |            |            |            |             |             |             |             |             |             |
|                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Cash flows from financing activities                                                                                |            |                          |            |                |            |            |            |            |             |             |             |             |             |             |
| Dividends to shareholders                                                                                |            | (8,839)                  |            | (8,905)        |            |            |            |            |             |             |             |             |             |             |
| Repurchase of common stock                                                                                |            | (2,150)                  |            | (4,838)        |            |            |            |            |             |             |             |             |             |             |
| Proceeds from short-term debt, net                                                                                |            | 11,984                   |            | 12,462         |            |            |            |            |             |             |             |             |             |             |
| Repayment of short-term debt, net                                                                                |            | (8,354)                  |            | (21,645)       |            |            |            |            |             |             |             |             |             |             |
| Proceeds from long-term debt, net of issuance costs                                                                      |            | 6,660                    |            | —              |            |            |            |            |             |             |             |             |             |             |
| Repayment of long-term debt                                                                                |            | (804)                    |            | (502)          |            |            |            |            |             |             |             |             |             |             |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net                                |            | 714                      |            | 907            |            |            |            |            |             |             |             |             |             |             |
| Credit support agreements activity, net                                                                                |            | 5                        |            | 62             |            |            |            |            |             |             |             |             |             |             |
| Settlement of convertible debt acquired from Shockwave                                                                   |            | (970)                    |            | —              |            |            |            |            |             |             |             |             |             |             |
| Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation |            | —                        |            | 8,047          |            |            |            |            |             |             |             |             |             |             |
| Proceeds from Kenvue initial public offering                                                                             |            | —                        |            | 4,241          |            |            |            |            |             |             |             |             |             |             |
| Cash transferred to Kenvue at separation                                                                                |            | —                        |            | (1,114)        |            |            |            |            |             |             |             |             |             |             |

---

| Column 1                                                        | Column 2   | Column 3                   | Column 4   | Column 5        | Column 6   | Column 7       | Column 8   | Column 9        | Column 10   | Column 11   | Column 12   | Column 13   | Column 14   | Column 15   | Column 16   | Column 17   | Column 18   | Column 19   | Column 20   | Column 21   | Column 22   | Column 23   | Column 24   | Column 25   | Column 26   | Column 27   |
|:----------------------------------------------------------------|:-----------|:---------------------------|:-----------|:----------------|:-----------|:---------------|:-----------|:----------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|:------------|
|                                                                 |            |                            |            |                 |            |                |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                                 |            | Fiscal Third Quarter Ended |            |                 |            |                |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|                                                                 |            | September 29,2024          |            | Percentto Sales |            | October 1,2023 |            | Percentto Sales |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Sales to customers (Note 9)                                     |            | $22,471                    |            | 100.0           | %          |                | $21,351    |                 | 100.0       | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Cost of products sold                                           |            | 6,963                      |            |                 | 31.0       |                |            | 6,606           |             | 30.9        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Gross profit                                                    |            | 15,508                     |            |                 | 69.0       |                |            | 14,745          |             | 69.1        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Selling, marketing and administrative expenses                  |            | 5,478                      |            |                 | 24.3       |                |            | 5,400           |             | 25.3        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Research and development expense                                |            | 4,952                      |            |                 | 22.0       |                |            | 3,447           |             | 16.2        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| In-process research and development impairments                 |            | —                          |            |                 | —          |                |            | 206             |             | 1.0         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest income                                                 |            | (292)                      |            |                 | (1.3)      |                |            | (374)           |             | (1.7)       |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Interest expense, net of portion capitalized                    |            | 193                        |            |                 | 0.9        |                |            | 192             |             | 0.9         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Other (income) expense, net                                     |            | 1,798                      |            |                 | 8.0        |                |            | 499             |             | 2.3         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Restructuring (Note 12)                                         |            | 41                         |            |                 | 0.2        |                |            | 158             |             | 0.7         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Earnings before provision for taxes on income                   |            | 3,338                      |            |                 | 14.9       |                |            | 5,217           |             | 24.4        |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Provision for taxes on income (Note 5)                          |            | 644                        |            |                 | 2.9        |                |            | 908             |             | 4.2         |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings from continuing operations                         |            | 2,694                      |            |                 | 12.0       | %              |            | 4,309           |             | 20.2        | %           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings from discontinued operations, net of tax (Note 13) |            | —                          |            |                 |            |                | 21,719     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings                                                    |            | $2,694                     |            |                 |            |                | $26,028    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Net earnings per share (Note 8)                                 |            |                            |            |                 |            |                |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Continuing operations - basic                                   |            | $1.12                      |            |                 |            |                | $1.71      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Discontinued operations - basic                                 |            | —                          |            |                 |            |                | 8.61       |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Total net earnings per share - basic                            |            | $1.12                      |            |                 |            |                | $10.32     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Continuing operations - diluted                                 |            | $1.11                      |            |                 |            |                | $1.69      |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Discontinued operations - diluted                               |            | —                          |            |                 |            |                | 8.52       |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Total net earnings per share - diluted                          |            | $1.11                      |            |                 |            |                | $10.21     |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Avg. shares outstanding                                         |            |                            |            |                 |            |                |            |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Basic                                                           |            | 2,407.2                    |            |                 |            |                | 2,522.9    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
| Diluted                                                         |            | 2,427.9                    |            |                 |            |                | 2,549.7    |                 |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |

---

English News:
**Johnson & Johnson's Financial Dynamics: Darzalex Expansion and Asset Growth Amidst Earnings Decline** Johnson & Johnson's strategic positioning in the pharmaceutical market is receiving a boost with the European label expansion of Darzalex for newly diagnosed multiple myeloma patients, following its recent approval by the U.S. Food and Drug Administration. This development is expected to significantly enhance the company's revenue stream. Darzalex is projected to generate $11.5 billion in revenue this year, with analysts forecasting potential growth to $20 billion annually by 2030. This promising outlook underscores the drug's critical role in Johnson & Johnson's future financial performance. Despite the promising prospects of Darzalex, Johnson & Johnson's net earnings for the fiscal third quarter ending September 29, 2024, saw a substantial decrease to $2,694 million, compared to $26,028 million for the same period in 2023. This decline in earnings may be attributed to specific operational cost increases or shifts in market conditions, impacting the overall financial outcomes for the period. On a positive note, the company's total assets increased from $167,558 million as of December 31, 2023, to $178,287 million as of September 29, 2024. This rise highlights a robust growth in Johnson & Johnson's asset base, driven largely by increases in goodwill and intangible assets. The expansion of these assets reflects a continued investment in the company's long-term strategic projects and adaptability in a competitive market environment. As Johnson & Johnson navigates these financial currents, the interplay between their strategic drug portfolio and broader market factors will be pivotal in shaping the company's financial trajectory in the coming years. The potential revenue growth from Darzalex stands as a testament to the ongoing innovation and adaptability inherent in Johnson & Johnson's operational ethos.

Chinese News:
强生携百余款创新产品七赴进博之约 近四分之一为首秀首发 第七届中国国际进口博览会即将到来。作为进博会“全勤生”，此次进博会，强生将以“创新于行，关爱于心”为主题，聚焦医疗科技和创新制药两大业务板块，携百余款创新产品亮相医疗器械及医药保健展区7.2馆，其中约四分之一为首秀首发产品。 本届进博会，强生展台专门设立明星产品展区，展出包括2款“全球首发”、20余款“中国首秀、首发”前沿创新产品。在创新制药领域，治疗非小细胞肺癌成人患者的双特异性抗体Rybrevant®和中国首个且目前唯一治疗BRCA突变转移性去势抵抗性前列腺癌的复方制剂泽倍珂®等重磅展品亮相。医疗科技领域则云集目前应用于肺癌诊疗的MONARCH®经自然腔道诊疗机器人、心力衰竭治疗领域的重磅创新产品Impella®CPwith SmartAssist介入式左心室辅助泵、应用于心血管微创外科手术的普诺瓦®缝线、创新桨型设计一次性使用磁定位标测导管OPTRELL、专为亚洲错颌畸形患者设计的矫形内固定系统MatrixORTHOGNATHIC LOCK，以及专为提供全视程视力设计的创新人工晶状体TECNISOdyssey赛无级®等全球尖端医疗科技产品和解决方案。 与此同时，强生医疗科技业务面向生物和技术的交叉领域开展创新，其展区专注外科、心脑血管、骨科和眼健康领域，带来一系列更智能、更微创、更个性化的创新产品和解决方案，通过实物展出和多媒体交互功能设备展现等形式，让观众亲身体验强生的医疗产品和技术。 强生医疗科技中国区总裁周敏涛表示：“进博会是政府推进高水平对外开放、支持高质量发展和打造更优营商环境的重要举措。从‘头回客’‘回头客’到‘常驻客’，强生高度重视进博会这一开放、创新和合作的重要平台。作为进博七届全勤生，我们获益于进博会带来的磁场效应和广泛影响，也深刻感受到中国经济的强劲韧性和市场的强大活力。强生医疗科技致力于以创新服务病患，期待与各方再次相约进博，共享医疗科技创新成果，共同迈向一个更加美好的健康未来。” 强生创新制药业务致力于科学地开拓医药行业的未来，其展区聚焦肿瘤、免疫、神经科学和心肺疾病等疾病领域重磅产品，全面展现了其以科学为本、使命为上、患者为先的创新理念，和为患者带来新生希望的使命担当。 强生创新制药中国区总裁CherryHuang表示：“进博会是众多创新药品的‘聚光灯’，促进各方合作的‘催化剂’，也是企业发展的‘助推器’。对于强生创新制药而言，进博会不仅是展示自身众多创新药品和突破性疗法的重要契机，更是加深了解中国医疗健康市场、促进医疗健康产业交流与合作的重要平台。我们期待借助进博会平台，将更多全球领先的创新药品加速引入中国，服务更多中国患者的健康需求，推动医疗卫生产业不断向前发展。” 强生表示，展望未来，公司将继续扎根中国，充分发挥医疗健康行业领军者的角色，抓住市场发展带来的新机遇，在加速创新研发的同时，积极推动本土创新合作，助力提升创新医疗健康产品和解决方案的可及性和可负担性，为中国百姓健康和医疗健康产业的高质量发展不断作出新的积极贡献。

Japanese News:
ジョンソン・エンド・ジョンソン（J&J）は、2024年度第3四半期の決算を発表し、事業売上高が6.3%増の225億ドルに達しました。米国での売上高は7.6%増、海外での売上高は4.6%増加し、全体的に好調な業績を記録しました。同社は3四半期連続で通期見通しを引き上げ、特にイノベーティブ・メディスン部門とMedTech部門の強さが際立ちました。 主なポイント: 事業売上高は6.3%増の225億ドル 米国の売上高が7.6%増、海外の売上高が4.6%増 純利益は27億ドル、EPS（希薄化後）は1.11ドル 調整後事業EPS見通しを9.91ドルに引き上げ イノベーティブ・メディスン部門の売上高は2四半期連続で140億ドル超 2024年度の調整後事業売上高成長率見通しを5.7%～6.2%に引き上げ 業績の詳細 イノベーティブ・メディスン部門は、11の主要ブランドが二桁成長を達成し、特にDARZALEXの四半期売上高が30億ドルを超えました。また、RYBREVANTとTREMFYAはFDAからの承認を受け、同社の成長をさらに加速させています。 MedTech部門は79億ドルの売上高を記録し、6.4%の成長を達成しました。特にAbiomed事業は16.3%の顕著な成長を報告し、Impella技術の世界的採用が順調に進んでいます。 逆風と課題 一方で、同社はいくつかの課題にも直面しました。NM26二重特異性抗体とタルク訴訟の和解に関連して12億5000万ドルの費用が発生しました。また、アジア太平洋地域、特に中国では量ベースの調達とマクロ経済圧力により課題が生じました。 今後の見通し ジョンソン・エンド・ジョンソンは、革新的な製品提供の勢いが今後も続くと予想しており、医薬品パイプラインでの大きな進展を見込んでいます。心血管部門とビジョン部門でのパフォーマンス改善が期待されており、様々な部門での新製品発売が第4四半期以降の成長を牽引すると予測されています。

Spanish News:
Johnson & Johnson ha publicado sus resultados del tercer trimestre de 2024, superando las estimaciones del mercado y anunciando un dividendo para el cuarto trimestre. Este desempeño le ha permitido aumentar sus previsiones de beneficios y ventas para el resto del año. Resultados clave: Beneficio neto: 2.694 millones de dólares, lo que representa una caída del 37,5% en comparación con los 4.309 millones de dólares del mismo período del año anterior. Beneficio por acción (BPA): 2,42 dólares, por encima de los 2,21 dólares esperados por el consenso. Ingresos: 22.471 millones de dólares, un aumento del 5,2% respecto a los 21.351 millones de dólares del tercer trimestre de 2023, superando los 22.200 millones de dólares proyectados. Desempeño por segmentos: Innovative Medicine: Las ventas operativas globales aumentaron un 6,3%, impulsadas por productos clave en oncología como Darzalex, Erleada y Carvykti, así como Tremfya en inmunología y Spravato en neurociencia. Sin embargo, el crecimiento fue parcialmente contrarrestado por la caída en las ventas de Stelara y Simponi. MedTech: Las ventas aumentaron un 6,4%, respaldadas por adquisiciones y desinversiones que contribuyeron en un 2,7%. El crecimiento fue impulsado principalmente por productos en electrofisiología, Abiomed en cardiovascular, lentes de contacto en visión y productos para el cierre de heridas en cirugía general. El crecimiento se vio parcialmente compensado por la caída en las ventas de productos en cirugía avanzada. Perspectivas para 2024: Johnson & Johnson ha actualizado su previsión de ganancias operativas ajustadas, reflejando un rendimiento mejorado y el impacto de la reciente adquisición de V-Wave. Ahora, estima que el beneficio por acción se situará en 10,15 dólares, con ventas proyectadas entre 89.400 y 89.800 millones de dólares, frente a las previsiones previas de entre 89.200 y 89.600 millones de dólares. No obstante, la empresa espera ganar entre 9,86 y 9,96 dólares por acción en 2024, incluidos los cargos relacionados con fusiones y adquisiciones, una estimación por debajo del rango previo de 10 a 10,10 dólares por acción. Dividendo anunciado: La Junta Directiva de Johnson & Johnson ha declarado un dividendo en efectivo de 1,24 dólares por acción para el cuarto trimestre de 2024. El dividendo será pagado el 10 de diciembre de este año a los accionistas registrados al cierre de operaciones el 26 de noviembre. La fecha ex-dividendo será el 26 de noviembre. Declaraciones: Joaquín Duato, presidente y CEO de Johnson & Johnson, comentó: "Los sólidos resultados de Johnson & Johnson en el tercer trimestre reflejan la amplitud única de nuestro negocio y el compromiso de ofrecer la próxima ola de innovación en el cuidado de la salud."

Greek News:
Θετικά οικονομικά αποτελέσματα ανακοίνωσε η Johnson & Johnson για το τρίτο οικονομικό τρίμηνο που έληξε στις 29 Σεπτεμβρίου 2024, καταγράφοντας αύξηση των καθαρών πωλήσεων και ενισχυμένες επενδύσεις στον τομέα του R&D. Συγκεκριμένα, οι πωλήσεις προς πελάτες ανήλθαν σε 22,47 δισεκατομμύρια δολάρια, σημειώνοντας αύξηση σε σύγκριση με τα 21,35 δισεκατομμύρια δολάρια την αντίστοιχη περίοδο του 2023. Αυτή η άνοδος συνέβαλε σε αύξηση του μικτού κέρδους, το οποίο διαμορφώθηκε στα 15,51 δισεκατομμύρια δολάρια ή στο 69,0% των πωλήσεων, έναντι 14,75 δισεκατομμυρίων δολαρίων ή 69,1% το προηγούμενο έτος. Παρά τη σχετική σταθερότητα στο περιθώριο μικτού κέρδους, η αύξηση κατά 763 εκατομμύρια δολάρια στο απόλυτο μέγεθος του μικτού κέρδους αντικατοπτρίζει τη θετική πορεία των συνολικών πωλήσεων. Παράλληλα, κατά τους πρώτους εννέα μήνες του οικονομικού έτους, οι δαπάνες για Έρευνα και Ανάπτυξη αυξήθηκαν ως ποσοστό επί των πωλήσεων. Η αύξηση αυτή οφείλεται, σε μεγάλο βαθμό, στην επένδυση ύψους 1,25 δισεκατομμυρίων δολαρίων για την εξασφάλιση των παγκόσμιων δικαιωμάτων του διειδικού αντισώματος NM26, μέσω της εξαγοράς της Yellow Jersey. Επιπλέον, σημαντικό ρόλο διαδραμάτισε και η χρονική κατανομή των εξόδων στον τομέα MedTech, ενισχύοντας τις συνολικές δαπάνες στο R&D.

Question:
What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.

Answer:

Question: What trends can be observed in the company’s revenue amount over the past few years? Please quote the piece(s) of news aligned with the finding(s), if any.